Impact Biomedical Gains 86% After-Hours on Merger Amendment Extending Deal to July 2026
Impact Biomedical’s shares jumped 86.28% after-hours on an amendment extending its merger deadline to July 1, 2026. Revised terms grant Dr Ashleys Bio Labs 94.20% of shares at closing and allot up to 128,000 shares to DSS, Inc. for funding and hold harmless obligations.
1. Merger Timeline Extended
Impact Biomedical filed amendments to its June 21, 2025 merger and share exchange agreement, extending the deal’s closing deadline from March 31 to July 1, 2026.
2. Adjusted Share Allocation
Under revised terms, Cayman Islands–based Dr Ashleys Bio Labs Limited will receive 169.5 million ordinary shares, representing 94.20% of total issued shares, while DSS, Inc. obtains 53,000 closing shares and an additional 75,000 shares upon meeting funding obligations.
3. Market Reaction and Trading Metrics
Shares rallied 86.28% after-hours and are trading near the 52-week low of $0.36 following a 71.30% annual decline; the company has a market capitalization of $43.24 million and an RSI of 39.62.